Inflammatory bowel disease following solid organ transplantation

Clinical Immunology

Volumn 128, Issue 3, 2008, Pages 287-293

  Hampton, Daniel D ^a   Poleski, Martin H ^a   Onken, Jane E ^a  

^a Inflammatory Bowel Disease Clinic   (United States)

Author keywords

DAMPs; Immune tolerance; Immunosuppression; Inflammatory bowel disease; PAMPs; Solid organ transplant

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BASILIXIMAB; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; GANCICLOVIR; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BLOODY DIARRHEA; CASE REPORT; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; ENTERITIS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; T LYMPHOCYTE;

ADULT; CYTOKINES; CYTOMEGALOVIRUS; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTE SUBSETS;

EID: 49149121833     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.06.011     Document Type: Short Survey

References (50)

1. Wörns M.A., Lohse A.W., Neurath M.F., Croxford A., Otto G., Kreft A., Galle P.R., and Kanzler S. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am. J. Gastroenterol. 101 (2006) 1931-1937
2. Papadakis K.A., Matuk R., Abreu M.T., Vasiliauskas E.A., Fleshner P.R., Lechago J., Tran T., Poordad F.F., Martin P., Vierling J., and Targan S.R. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut 53 (2004) 1389-1390
3. Anumakonda V., Hayee B., and Chung-Faye G. Remission and relapse of Crohn's disease following autologous haematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Gut 56 (2007) 1325
4. Harpaz N., Ruf A.E., Shukla D., Tao Y., Fishbein T.M., Sauter B.V., and Gondolesi G.E. Early and frequent histological recurrence of Crohn's disease in small intestinal allografts. Transplantation 80 (2005) 1667-1670
5. Verdonk R.C., Dijkstra G., Haagsma E.B., Shostrom V.K., Van den Berg A.P., Kleibeuker J.H., Langnas A.N., and Sudan D.L. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am. J. Transp. 6 (2006) 1422-1429
6. Haagsma E.B., Van Den Berg A.P., Kleibeuker J.H., Slooff M.J., and Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment. Pharmacol. Ther. 18 (2003) 33-44
7. Papatheodoridis G.V., Hamilton M., Mistry P.K., Davidson B., Rolles K., and Burroughs A.K. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 43 (1998) 639-644
8. Cummings J.R., Keshav S., and Travis S.P. Medical management of Crohn's disease. BMJ 336 (2008) 1062-1066
9. Post D.J., Douglas D.D., and Mulligan D.C. Immunosuppression in liver transplantation. Liver Transplant. 11 (2005) 1307-1314
10. Summers R.W., Sessions Jr. J.T., Becktel J.M., Best W.R., Kern Jr. F., and Singleton J.W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 (1979) 847
11. Olaison G., Sjodahl R., and Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31 (1990) 325-328
12. Herold M.J., McPherson M.J., and Reichardt H.M. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. 63 (2006) 60-72
13. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., and Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330 (1994) 1841-1845
14. Stange E.F., Modigliani R., Peña A.S., Wood A.J., Feutren G., and Smith P.R. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study, The European Study Group. Gastroenterology 109 (1995) 774-782
15. Sandborn W.J., Present D.H., Isaacs K.L., Wolf D.C., Greenberg E., Hanauer S.B., Feagan B.G., Mayer L., Johnson T., Galanko J., Martin C., and Sandler R.S. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125 (2003) 380-388
16. Neurath M.F., Wanitschke R., Peters M., Krummenauer F., Meyer zum Buschenfelde K.H., and Schlaak J.F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44 (1999) 625-628
17. Fellermann K., Steffen M., Stein J., Raedler A., Hamling J., Ludwig D., Loeschke K., and Stange E.F. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment. Pharmacol. Ther. 14 (2000) 171-176
18. A. Timmer, J.W. McDonald, J.K. Macdonald, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database of Systematic Reviews (2007) CD000478.
19. W. Sandborn, L. Sutherland, D. Pearson, G. May, R. Modigliani, C. Prantera, Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease, Cochrane Database of Systematic Reviews (2000) CD000545.
20. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., Lehr H.A., Wirtz S., Becker C., Atreya R., Mudter J., Hildner K., Bartsch B., Holtmann M., Blumberg R., Walczak H., Iven H., Galle P.R., Ahmadian M.R., and Neurath M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111 (2003) 1133-1145
21. Mitoma H., Horiuchi T., Tsukamoto H., Tamimoto Y., Kimoto Y., Uchino A., To K., Harashima S., Hatta N., and Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 58 (2008) 1248-1257
22. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
23. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., and Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF{alpha} therapy. J. Exp. Med. 200 (2004) 277-285
24. Lugering A., Lebiedz P., Koch S., and Kucharzik T. Apoptosis as a therapeutic tool in IBD?. Ann. NY Acad. Sci. 1072 (2006) 62-77
25. Land W., Schneeberger H., Schleibner S., Illner W.D., Abendroth D., Rutili G., Arfors K.E., and Messmer K. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 57 (1994) 211-217
26. Land W. Innate alloimmunity: history and current knowledge. Experimental and Clinical Transplantation 5 (2007) 575-584
27. Foell D., Wittkowski H., Vogl T., and Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc Biol. 81 (2007) 28-37
28. Kaiser T., Langhorst J., Wittkowski H., Becker K., Friedrich A.W., Rueffer A., Dobos G.J., Roth J., and Foell D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56 (2007) 1706-1713
29. Abreu M.T., Thomas L.S., Arnold E.T., Lukasek K., Michelsen K.S., and Arditi M. TLR signaling at the intestinal epithelial interface. J. Endotoxin Res. 9 (2003) 322-330
30. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68 (2000) 7010-7017
31. Friedman A., and Weiner H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. 91 (1994) 6688-6692
32. Melamed D., and Friedman A. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression. Eur. J. Immunol. 24 (1994) 1974-1981
33. Whitacre C.C., Gienapp I.E., Orosz C.G., and Bitar D.M. Oral tolerance in experimental autoimmune encephalomyelitis: III. Evidence for clonal anergy. J. Immunol. 147 (1991) 2155-2163
34. Chen Y., Inobe J.-i., Marks R., Gonnella P., Kuchroo V.K., and Weiner H.L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376 (1995) 177-180
35. Neurath M.F., Finotto S., Fuss I., Boirivant M., Galle P.R., and Strober W. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22 (2001) 21-26
36. Freire-de-Lima C.G., Nascimento D.O., Soares M.B., Bozza P.T., Castro-Faria-Neto H.C., de Mello F.G., DosReis G.A., and Lopes M.F. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403 (2000) 199-203
37. Hale L.P., Gottfried M.R., and Swidsinski A. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm. Bowel Dis. 11 (2005) 1060-1069
38. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., and Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 183 (1996) 2605-2616
39. Fuss I.J., Boirivant M., Lacy B., and Strober W. The interrelated roles of TGF-{beta} and IL-10 in the regulation of experimental colitis. J. Immunol. 168 (2002) 900-908
40. Oida T., Zhang X., Goto M., Hachimura S., Totsuka M., Kaminogawa S., and Weiner H.L. CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J. Immunol. 170 (2003) 2516-2522
41. Nakano Y., Monden M., Valdivia L.A., Gotoh M., Tono T., and Mori T. Permanent acceptance of liver allografts by intraportal injection of donor spleen cells in rats. Surgery 111 (1992) 668-676
42. Li W., Chou S.T., Wang C., Kuhr C.S., and Perkins J.D. Role of the liver in peripheral tolerance: induction through oral antigen feeding. Am. J. Transp. 4 (2004) 1574-1582
43. Strauss G., Osen W., and Debatin K.M. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin. Exp. Immunol. 128 (2002) 255-266
44. Takahashi K., Reynolds M., Ogawa N., Longo D.L., and Burdick J. Augmentation of T-cell apoptosis by immunosuppressive agents. Clin. Transplant. 18 (2004) 72-75
45. Izeradjene K., and Revillard J.P. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation 71 (2001) 118-125
46. Wessels J.A., Huizinga T.W., and Guchelaar H.J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47 (2008) 249-255
47. Baan C.C., Balk A.H., van Riemsdijk I.C., Vantrimpont P.J., Maat A.P., Niesters H.G., Zondervan P.E., van Gelder T., and Weimar W. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. Transplantation 75 (2003) 1704-1710
48. Praditpornsilpa K., Avihingsanon Y., Kupatawintu P., Songpanich S., Pisitkul T., Kansanabuch T., Eiam-Ong S., Chusil S., O-Charoen R., and Tungsanga K. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody. Transplant. Proc. 36 (2004) S487-S491
49. Janssen O., Wesselborg S., and Kabelitz D. Immunosuppression by OKT3-induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 53 (1992) 233-234
50. Tchilian E.Z., Owen J.J., and Jenkinson E.J. Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells. Immunology 92 (1997) 321-327